Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J2002; 324: 71–86.
2.
RothwellPM, FowkesFGR, BelchJFF. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet2011; 377(9759):31–41.
3.
BroeGA, CraysonDA, CreaseyHM. Anti-inflammatory drugs against Alzeimer disease at low doses. Arch Neurol2000; 57(11):1586–91.
4.
BaigentC, BlackwellL. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009; 372: 1849–60.
5.
GazianoJM, BrotonsC, CoppolecchiaR. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392(10152):1036–46.
6.
GroupASC, BowmanL, MafhamM. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379(16):1529–39.
7.
McNeilJJ, WolfeR, WoodsRL. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379(16):1509–18.
8.
BhattDL, ScheimanJ, AbrahamNS. ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol2008; 103:2890–2907.
9.
MahadySE, MargolisKL, ChanA. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut2020; 0:1-8, doi: 10.1136/ gutjnl-2020-321585.
10.
SavjiN, RockmanCB, SkolnickAH. association between advanced age and vascular disease in different arterial territories: a population database over 3.6 million subjects. J Am Coll Cardiol. 2013 Apr 23; 61(16):1736–43.
11.
ArnettDK, BlumenthalRS, AlbertMA. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/ American heart association Task force on clinical practice guidelines. Circulation2019; 140: e596-646.
